Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 55.11

-2.6%

Nov 7 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scott_jiminez who wrote (1995)	11/8/2000 11:14:16 AM
From: Biomaven	Read Replies (3) of 52153

Looks to me like the ultra-slim mandate and the ultra-slim majorities in Congress will mean that nothing too dramatic will be done in the way of governance, which is fine by me. (Personally I would have been much happier with some sort of split rather than one party controlling the house, senate and the executive). From a biotech perspective, we clearly aren't going to see much in the way of cost-control for drugs, and SGP will have a renewed shot at a patent extension for Claritin (which would be good for SEPR). We also should see the FDA user fee legislation renewed without too much fuss, which is a significant issue that hasn't been discussed much. Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next